Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Reports Steep Increase in Revenues, Sightly Narrowed Net Loss

NEW YORK, April 23 (GenomeWeb News) - Gene Logic reported a steep increase in revenues and slightly narrowed losses for the first quarter today.


Revenues for the quarter climbed to $20.2 million, from $12.7 million during the same period last year. The company attributed most of this increase to revenues from Gene Logic Laboratories, formerly TherImmune Resaerch, which it acquired last April.


Research and development costs decreased to $0.4 million, from $0.6 million during the first quarter of 2003.


Gene Logic's net loss narrowed to $5.5 million, or $.18 per share, from $5.8 million, or $.21 per share, for the first quarter last year.


As of March 31, Gene Logic had $110.8 million in cash, cash equivalents, and marketable securities, of which $53.7 million were cash and cash equivalents.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.